CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
| 适应症 | Acute Lymphoblastic Leukemia |
|---|---|
| 分期 | 2期 |
| 申办方 | M.D. Anderson Cancer Center |
| 状态 | 已完成 |
| 受试者人数 | 90 人 |
| 干预（药物） | CMC-544 (Inotuzumab Ozogamycin), Rituximab |
| 开始日期 | 2010年6月4日 |
| 完成日期 | 2018年4月18日 |
| 结果公布日 | 2019年5月22日 |
摘要
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Number of Patients With Response
| Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2 | 3 Participants |
|---|---|
| Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2 | 25 Participants |
| Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin) | 24 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual — National Cancer Institute (NCI)
- Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute — Wake Forest University Health Sciences